Clinical trial
An Open-Label Biomarker Study of BHV-1300 in Graves' Disease
NCT06980649 is registered in ClinicalTrials.gov with Biohaven Therapeutics Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Biomarker Study of BHV-1300 in Graves' Disease
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- August 21, 2025
- Completion date
- September 30, 2027
- Enrollment
- 15 (estimated)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.